Tobias M Gorges
Overview
Explore the profile of Tobias M Gorges including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1366
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Strati A, Zavridou M, Kallergi G, Politaki E, Kuske A, Gorges T, et al.
Clin Chem
. 2021 Jul;
67(10):1395-1405.
PMID: 34322698
Background: Circulating tumor cell (CTC) analysis is highly promising for liquid biopsy-based molecular diagnostics. We undertook a comprehensive molecular analysis of in vivo isolated CTCs in breast cancer (BrCa). Methods:...
2.
Bartkowiak K, Heidrich I, Kwiatkowski M, Gorges T, Andreas A, Geffken M, et al.
Cancers (Basel)
. 2021 Feb;
13(3).
PMID: 33540545
(1) Background: the early detection of cancer cells in the blood or bone marrow of breast cancer patients improves the understanding of metastasis. Disseminating tumor cells in the bone marrow...
3.
Koch C, Kuske A, Joosse S, Yigit G, Sflomos G, Thaler S, et al.
EMBO Mol Med
. 2020 Jul;
12(9):e11908.
PMID: 32667137
Functional studies giving insight into the biology of circulating tumor cells (CTCs) remain scarce due to the low frequency of CTCs and lack of appropriate models. Here, we describe the...
4.
Bartkowiak K, Koch C, Gartner S, Andreas A, Gorges T, Pantel K
Cells
. 2020 May;
9(5).
PMID: 32466213
Background: Solid epithelial tumors like breast cancer are the most frequent malignancy in women. Circulating tumor cells (CTCs) are frequently released from hypoxic areas into the blood, where CTCs face...
5.
Koch C, Joosse S, Schneegans S, Wilken O, Janning M, Loreth D, et al.
Cancers (Basel)
. 2020 Feb;
12(2).
PMID: 32069934
Circulating tumor cells (CTCs) are promising tools for risk prediction and the monitoring of response to therapy in cancer patients. Within the EU/IMI CANCER-ID consortium, we validated CTC enrichment systems...
6.
Gorges K, Wiltfang L, Gorges T, Sartori A, Hildebrandt L, Keller L, et al.
Cancers (Basel)
. 2019 Nov;
11(11).
PMID: 31671846
Despite remarkable progress in melanoma therapy, the exceptional heterogeneity of the disease has prevented the development of reliable companion biomarkers for the prediction or monitoring of therapy responses. Here, we...
7.
Joosse S, Beyer B, Gasch C, Nastaly P, Kuske A, Isbarn H, et al.
Clin Chem
. 2019 Oct;
66(1):161-168.
PMID: 31601564
Background: Transrectal ultrasound-guided prostate biopsy (TRUS) is a standard procedure for prostate cancer diagnosis. Because prostate cancer is a multifocal disease in many patients, multiple sampling (n ≥ 10) is...
8.
Hille C, Gorges T, Riethdorf S, Mazel M, Steuber T, von Amsberg G, et al.
Cells
. 2019 Sep;
8(9).
PMID: 31514447
Expression of the androgen receptor splice variant 7 ( in circulating tumor cells (CTCs) has been associated with resistance towards novel androgen receptor (AR)-targeting therapies. While a multitude of ARV7...
9.
Janning M, Kobus F, Babayan A, Wikman H, Velthaus J, Bergmann S, et al.
Cancers (Basel)
. 2019 Jun;
11(6).
PMID: 31212989
Circulating tumor cells (CTCs) hold great potential to answer key questions of how non-small cell lung cancer (NSCLC) evolves and develops resistance upon anti-PD-1/PD-L1 treatment. Currently, their clinical utility in...
10.
El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, et al.
Clin Chem
. 2018 Jan;
64(3):536-546.
PMID: 29301749
Background: Liquid biopsies can be used in castration-resistant prostate cancer (CRPC) to detect androgen receptor splice variant 7 (AR-V7), a splicing product of the androgen receptor. Patients with AR-V7-positive circulating...